InsidersTradesSigma
Follow the Indaptus Therapeutics, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Indaptus Therapeutics, Inc. has recorded 18 insider filings. Market capitalisation: €337.1m. The latest transaction was filed on 22 January 2026 (Attribution). Among the most active insiders: Meckler Jeffrey A. The full history is openly available.
18
Insider Decl.
n/a
Thresholds
€288,480
9 ops.
Buy Volume
€26,318
1 ops.
Sell Volume
48Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 22 January 2026
Declarations18 total
25,000 shares0Common StockSEC:0001493152-26-003293:0
216,617 shares@ US$2.0345.9% of flowCommon StockSEC:0001493152-25-029355:0
52,204 shares@ US$2.0377.5% of flowCommon StockSEC:0001493152-25-029354:0
54,421 shares@ US$2.0399.6% of flowCommon StockSEC:0001493152-25-029353:0
6,068 shares@ US$8.30249.7% of flowCommon StockSEC:0001641172-25-021376:0
42,553 shares@ US$1.1759.0% of flowCommon stockSEC:0001493152-24-047808:0
84,932 shares@ US$1.82526.9% of flowCommon stockSEC:0001493152-24-030839:0
44,354 shares@ US$1.94100.0% of flowCommon StockSEC:0001493152-23-029212:0
Canonical exit: 8 Nov 2023 (T+90)
100 shares@ US$4.65100.0% of flowCommon StockSEC:0001493152-22-035926:0
Canonical exit: 1 May 2022 (T+90)
400 shares@ US$1.76370.1% of flowCommon stockSEC:0001493152-22-033241:0
Canonical exit: 16 Feb 2023 (T+90)
10,308 shares@ US$2.805.5% of flowCommon stockSEC:0001493152-22-025578:0
Canonical exit: 7 Dec 2022 (T+90)
150 shares@ US$2.62100.0% of flowCommon stockSEC:0001493152-22-025450:0
Canonical exit: 6 Dec 2022 (T+90)
1,060 shares@ US$2.440.5% of flowCommon stockSEC:0001493152-22-025319:0
Canonical exit: 5 Dec 2022 (T+90)
19,727 shares@ US$2.630.95% mcap15.9% of flowCommon stockSEC:0001493152-22-016027:0
Canonical exit: 4 Sept 2022 (T+90)
5,870 shares@ US$5.00010.52% mcap50.0% of flowCommon StockSEC:0001493152-22-003002:0
11,187 shares@ US$5.821.13% mcap18.8% of flowCommon StockSEC:0001493152-21-029297:0
Canonical exit: 16 Feb 2022 (T+90)
12,000 shares@ US$7.008.7% of flowCommon StockSEC:0001493152-21-022936:0
Canonical exit: 13 Dec 2021 (T+90)
18 of 18 declarations
关于 Indaptus Therapeutics, Inc.
Indaptus Therapeutics, Inc. (股票代码：INDP) 是一家在美国上市的生物技术公司，在纳斯达克（因此在纽约证券交易所/纳斯达克生态系统）交易，总部位于美国纽约。该公司是一家临床阶段生物技术公司，专注于开发治疗癌症和病毒感染的新型疗法。其公司历史相对较新，反映了2021年围绕Decoy Biosystems资产进行的重组和品牌重塑，此后该公司开始以Indaptus Therapeutics的名义运营。作为一家早期生物技术公司的典型特征，该公司仍然是研发驱动型，运营历史有限，并依赖外部资本来推进开发。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1857044/000149315221018935/form8-k.htm?utm_source=openai)) Indaptus的核心业务围绕其专有的全身给药免疫疗法平台构建，该平台以其Decoy候选产品为中心，其中Decoy20目前是主要项目。其科学概念是提供一种静脉注射疗法，旨在激活抗肿瘤和抗病毒免疫反应。该公司在其材料中强调了临床前工作，该工作显示当Decoy候选产品与PD-1检查点抑制剂、低剂量化疗、非甾体抗炎药或已批准的靶向抗体联合使用时，肿瘤得以清除。Indaptus还强调了以安全为导向的设计，指出非临床毒理学研究未显示关键细胞因子释放综合征生物标志物的持续诱导，这可能有助于该平台在拥挤的免疫肿瘤学领域中脱颖而出。（[globenewswire.com](https://www.globenewswire.com/news-release/2025/06/02/3091794/0/en/indaptus-therapeutics-doses-first-patient-in-phase-1b-2-combination-study-of-decoy20-with-pd-1-checkpoint-inhibitor-tislelizumab.html)) 从竞争角度来看，Indaptus在生物技术领域最具竞争力的领域之一：免疫肿瘤学和抗病毒免疫疗法中运营。该公司不以规模、制造广度或商业基础设施进行竞争；相反，其价值主张在于科学差异化、专利保护以及创造组合方案以在不产生不可接受的毒性的情况下提高疗效的潜力。一个值得注意的战略步骤是该公司在中国、日本和以色列获得了涵盖用于预防或治疗乙型肝炎病毒和艾滋病毒的Decoy细菌组成的新专利。对于投资者而言，这支持了以知识产权为主导的论点：如果该平台能转化为临床效益，该公司可能会吸引合作兴趣或更广泛的开发机会。（[globenewswire.com](https://www.globenewswire.com/news-release/2025/03/13/3042088/0/en/indaptus-therapeutics-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-corporate-update.html)) 从地理上看，Indaptus主要位于美国，主要行政办公室设在纽约市哥伦布圆环3号；其SEC备案文件也提及了此前在加利福尼亚州圣地亚哥的办公空间。最近的里程碑突显了该公司的临床发展势头。2025年3月，Indaptus表示已与百济神州签订临床供应协议，以评估Decoy20与替雷利珠单抗的联合用药，并于2025年6月宣布在1b/2期扩展研究中给药首位患者。最近，该公司2026年第一季度的更新强调了该业务的前景和风险状况：开发正在推进，但融资需求、持续经营风险以及从临床前和早期临床数据到获批产品的不确定路径仍然是核心投资考量。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0001857044/000149315226010585/form10-k.htm))
